Comparative effectiveness of fenfluramine versus cannabidiol in their licensed indications for the treatment of seizures in Dravet Syndrome: a systematic review and network meta-analysis

W Linley, M Schwenkglenks, N Hawkins, T Toward
doi: https://doi.org/10.1101/2022.07.01.22277155

Article usage

Article usage: July 2022 to July 2025

AbstractFullPdf
Jul 20225431165
Aug 2022951231
Sep 20221121029
Oct 2022851730
Nov 2022741324
Dec 2022472823
Jan 2023603442
Feb 2023462446
Mar 2023522226
Apr 2023411628
May 2023344121
Jun 2023782425
Jul 2023522126
Aug 2023312317
Sep 2023431332
Oct 2023533321
Nov 2023671829
Dec 202330711
Jan 202431513
Feb 2024481015
Mar 202487433
Apr 202436920
May 202419213
Jun 2024211026
Jul 202433537
Aug 202428825
Sep 202453515
Oct 202420816
Nov 2024181020
Dec 20248110
Jan 2025221339
Feb 2025273715
Mar 2025404133
Apr 2025381626
May 2025411429
Jun 2025191021
Jul 2025215324
Back to top
Posted July 02, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Comparative effectiveness of fenfluramine versus cannabidiol in their licensed indications for the treatment of seizures in Dravet Syndrome: a systematic review and network meta-analysis
W Linley, M Schwenkglenks, N Hawkins, T Toward
medRxiv 2022.07.01.22277155; doi: https://doi.org/10.1101/2022.07.01.22277155
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area